ADAPY ADAPTIMMUNE THERAPEUTICS PLC revenue, earnings and financials

For the quarter ended June 30, 2025, ADAPTIMMUNE THERAPEUTICS PLC reported revenue of $13.7M (down 89.3% from a year earlier), net income of −$30.3M and diluted EPS of −$0.02; over the last four quarters revenue was $65.1M and net income −$170M; for the fiscal year ended December 2024 revenue was $178M, up 195.3% on the year before.

ADAPY annual revenue and earnings

• Fiscal year ended Dec 2024: revenue $178M, gross profit n/a, operating income −$68.8M, net income −$70.8M (margin -39.8%), EPS −$0.05
• Fiscal year ended Dec 2023: revenue $60.3M, gross profit n/a, operating income −$140M, net income −$114M (margin -188.9%), EPS −$0.09
• Fiscal year ended Dec 2022: revenue $27.1M, gross profit n/a, operating income −$164M, net income −$165M (margin -609.5%), EPS −$0.17
• Fiscal year ended Dec 2021: revenue $6.15M, gross profit n/a, operating income −$162M, net income −$158M (margin -2571.0%), EPS −$0.17

ADAPY quarterly revenue and earnings

• Quarter ended Jun 30, 2025: revenue $13.7M (down 89.3% year over year), net income −$30.3M, EPS −$0.02
• Quarter ended Mar 31, 2025: revenue $7.29M (up 28.3% year over year), net income −$47.6M, EPS −$0.03
• Quarter ended Dec 31, 2024 (from the annual report): revenue $3.22M (up 1294.8% year over year), net income −$74.2M, EPS −$0.05
• Quarter ended Sep 30, 2024: revenue $40.9M (up 458.8% year over year), net income −$17.6M, EPS −$0.01
• Quarter ended Jun 30, 2024: revenue $128M (up 2399.6% year over year), net income $69.5M, EPS $0.04
• Quarter ended Mar 31, 2024: revenue $5.68M (down 88.1% year over year), net income −$48.5M, EPS −$0.03
• Quarter ended Dec 31, 2023 (from the annual report): revenue $231K (down 97.9% year over year), net income −$47.9M, EPS −$0.04
• Quarter ended Sep 30, 2023: revenue $7.32M (up 4.5% year over year), net income −$45.6M, EPS −$0.03
• Quarter ended Jun 30, 2023: revenue $5.13M (down 7.4% year over year), net income −$21.4M, EPS −$0.02
• Quarter ended Mar 31, 2023: revenue $47.6M (up 1231.5% year over year), net income $1.04M, EPS $0.00
• Quarter ended Dec 31, 2022 (from the annual report): revenue $11.0M (up 678.3% year over year), net income −$29.3M, EPS −$0.03
• Quarter ended Sep 30, 2022: revenue $7.01M (up 482.5% year over year), net income −$41.4M, EPS −$0.04
• Quarter ended Jun 30, 2022: revenue $5.54M (up 78.9% year over year), net income −$44.5M, EPS −$0.05
• Quarter ended Mar 31, 2022: revenue $3.58M (up 723.7% year over year), net income −$50.3M, EPS −$0.05
• Quarter ended Dec 31, 2021 (from the annual report): revenue $1.42M, net income −$38.9M, EPS −$0.04
• Quarter ended Sep 30, 2021: revenue $1.20M, net income −$42.4M, EPS −$0.05
• Quarter ended Jun 30, 2021: revenue $3.10M, net income −$39.1M, EPS −$0.04
• Quarter ended Mar 31, 2021: revenue $434K, net income −$37.8M, EPS −$0.04

ADAPY cash flow, buybacks and dividends

• Fiscal year ended Dec 2024: operating cash flow −$73.2M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$141M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$142M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow $10.7M, share buybacks n/a

ADAPY balance sheet

• Jun 30, 2025: cash $26.1M, total assets $131M, total liabilities $202M, shareholders' equity −$71.0M, long-term debt $25.7M
• Mar 31, 2025: cash $41.1M, total assets $158M, total liabilities $196M, shareholders' equity −$37.4M, long-term debt $25.4M
• Dec 31, 2024: cash $91.1M, total assets $246M, total liabilities $234M, shareholders' equity $11.8M, long-term debt $50.2M
• Sep 30, 2024: cash $117M, total assets $317M, total liabilities $237M, shareholders' equity $80.0M, long-term debt $49.9M
• Jun 30, 2024: cash $212M, total assets $322M, total liabilities $225M, shareholders' equity $96.3M, long-term debt $25.0M
• Mar 31, 2024: cash $141M, total assets $258M, total liabilities $234M, shareholders' equity $24.4M
• Dec 31, 2023: cash $144M, total assets $283M, total liabilities $243M, shareholders' equity $39.5M
• Sep 30, 2023: cash $90.1M, total assets $297M, total liabilities $209M, shareholders' equity $88.1M

What is ADAPY's revenue?

ADAPTIMMUNE THERAPEUTICS PLC reported $65.1M of revenue over its last four quarters, through June 30, 2025.

Is ADAPY profitable?

No. ADAPTIMMUNE THERAPEUTICS PLC lost $170M over the last four quarters.

What is ADAPY's EPS?

Diluted earnings per share over the last four quarters were −$0.11; −$0.02 in the latest quarter.

ADAPY ownership and insider trades · All stocks